ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,180.74
1.03%
Dow Jones
38,852.27
0.46%
US Dollar vs MXN
16.8839
-0.59%
Brent Oil
83.38
0.31%
Bitcoin
63,425.73
-0.90%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. RAPT Therapeutics Inc (RAPT)

  7. RAPT Therapeutics Inc (RAPT) Noticias

RAPT

RAPT Therapeutics (RAPT)

RAPT Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:RAPT
FechaHoraFuenteTítuloSímboloCompañía
09/04/202411:00GlobeNewswire Inc.RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer PatientsNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202415:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202407:08Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RAPTRAPT Therapeutics Inc
07/03/202407:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202407:00GlobeNewswire Inc.RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
05/03/202415:30GlobeNewswire Inc.RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual MeetingNASDAQ:RAPTRAPT Therapeutics Inc
20/02/202406:30GlobeNewswire Inc.RAPT Therapeutics Announces Clinical Hold on Studies Evaluating ZelnecirnonNASDAQ:RAPTRAPT Therapeutics Inc
14/02/202407:52Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RAPTRAPT Therapeutics Inc
13/02/202407:00GlobeNewswire Inc.RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical OperationsNASDAQ:RAPTRAPT Therapeutics Inc
31/01/202407:00GlobeNewswire Inc.RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
02/01/202407:00GlobeNewswire Inc.RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
27/11/202307:00GlobeNewswire Inc.RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in AllergyNASDAQ:RAPTRAPT Therapeutics Inc
13/11/202307:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RAPTRAPT Therapeutics Inc
13/11/202307:00GlobeNewswire Inc.RAPT Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
03/11/202311:00GlobeNewswire Inc.RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLCNASDAQ:RAPTRAPT Therapeutics Inc
01/11/202315:05GlobeNewswire Inc.RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in NovemberNASDAQ:RAPTRAPT Therapeutics Inc
23/10/202315:40Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:RAPTRAPT Therapeutics Inc
18/10/202308:00GlobeNewswire Inc.RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingNASDAQ:RAPTRAPT Therapeutics Inc
30/08/202315:05GlobeNewswire Inc.RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in SeptemberNASDAQ:RAPTRAPT Therapeutics Inc
17/08/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RAPTRAPT Therapeutics Inc
11/08/202307:57Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RAPTRAPT Therapeutics Inc
11/08/202307:00GlobeNewswire Inc.RAPT Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
07/06/202307:00GlobeNewswire Inc.RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
26/05/202307:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RAPTRAPT Therapeutics Inc
25/05/202318:03Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RAPTRAPT Therapeutics Inc
25/05/202316:00GlobeNewswire Inc.RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced CancersNASDAQ:RAPTRAPT Therapeutics Inc
15/05/202315:13Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:RAPTRAPT Therapeutics Inc
11/05/202307:00GlobeNewswire Inc.RAPT Therapeutics Reports First Quarter 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
03/05/202307:00GlobeNewswire Inc.RAPT Therapeutics Announces the Appointment of Michael Listgarten as General CounselNASDAQ:RAPTRAPT Therapeutics Inc
26/04/202315:19GlobeNewswire Inc.RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:RAPTRAPT Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RAPT

Su Consulta Reciente

FX
USDMXN
US Dollar vs MXN
NYSE
BAC
Bank of America
SPI
SP500
S&P 500
NYSE
KO
Coca Cola
AMEX
XLF
Financial Select Sector
NASDAQ
GOOGL
Alphabet
NYSE
AXP
American Express
NASDAQ
AMZN
Amazon.com
NYSE
DIS
Walt Disney
AMEX
SPY
SPDR S&P 500
NYSE
MRK
Merck
NYSE
VZ
Verizon Communications
USOTC
RHHBY
Roche (QX)
NASDAQ
NVDA
NVIDIA
CCOM
US500
US 500
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados